Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia

NCT02241031 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Hematological Diseases
Thrombocytopenia

Interventions

BIOLOGICAL: MPs
DRUG: thrombopoietin (TPO) and interleukin-11

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]